Table 4.
Comparison of clinical end-points at various follow-up intervals for patients with and without PH Post-TAVR.
| Clinical end-points | In hospital | 6 months | |||||
| Without PH group (n = 55) | PH group (n = 48) | p | Without PH group (n = 55) | PH group (n = 48) | p | ||
| Primary endpoints | |||||||
| All-cause mortality, % | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | |
| Cardiovascular mortality, % | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | |
| Secondary endpoints | |||||||
| Bleeding event, % | 0 (0%) | 1 (2.1%) | 0.29 | 1 (1.8%) | 1 (2.1%) | 0.92 | |
| Major Vascular complication, % | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | |
| Acute renal failure, % | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | |
| Stroke, % | 0 (0%) | 1 (2.1%) | 0.29 | 1 (1.8%) | 2 (4.2%) | 0.48 | |
| Myocardial infarction, % | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | |
| New AF, % | 4 (7.3%) | 1 (2.1%) | 0.21 | 0 (0%) | 0 (0%) | - | |
| New LBBB, % | 12 (21.8%) | 6 (12.5%) | 0.20 | 1 (1.8%) | 0 (0%) | 0.35 | |
| New AVB, % | 11 (20.0%) | 13 (27.1%) | 0.42 | 6 (10.9%) | 3 (6.3%) | 0.40 | |
| New PPM, % | 9 (16.4%) | 14 (29.2%) | 0.13 | 2 (3.6%) | 3 (6.3%) | 0.54 | |
| Endocarditis, % | 0 (0%) | 0 (0%) | - | 0 (0%) | 0 (0%) | - | |
| Mild PVL, % | 3 (5.5%) | 7 (14.6%) | 0.12 | 5 (9.1%) | 6 (12.5%) | 0.58 | |
| Re-hospitalization, % | 0 (0%) | 0 (0%) | - | 1 (1.8%) | 3 (6.3%) | 0.25 | |
Abbreviations: AF, atrial fibrillation; LBBB, left bundle branch block; AVB, atrioventricular block; PPM, permanent pacemaker; PVL, perivalvular leakage; TAVR, transcatheter aortic valve replacement; PH, pulmonary hypertension.